

Press release

Rudolf Bär succeeds Roger Scarlett-Smith as Head of STADA UK Business

- Roger Scarlett-Smith has decided in mutual agreement with the STADA board to step down from his role as Head of UK; he now plans to retire
- Rudolf Bär has assumed responsibility for STADA's UK operations in addition to his current responsibilities as cluster head for Mid-Size European Markets
- Roger Scarlett-Smith: "There are phenomenal opportunities ahead for STADA and I wish Rudolf all the best as he assumes his wider responsibilities. I would like to thank the UK Senior Executive Committee and everyone in the business both locally and globally for their support."

Huddersfield – 5 September 2022 – Roger Scarlett-Smith has decided in mutual agreement with the STADA board to step down from his role as Head of UK. Scarlett-Smith has reached the end of his assignment and now plans to retire.

STADA CEO Peter Goldschmidt expressed his sincere appreciation for Scarlett-Smith's contribution over the past four years. During this time, he led the UK operation through the pandemic, the expansion and refitting of our Thornton & Ross manufacturing facility in Linthwaite, as well as the transfer of the commercial teams into purpose-built offices in nearby Slaithwaite.

Under Scarlett-Smith's leadership, the STADA UK business has grown sales by 50% and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation

Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez
Supervisory Board Chair: Dr. Günter von Au



regionally, being voted number 1 regional company last year and winning many national industry awards.

Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories.

Rudolf Bär has assumed responsibility for STADA's UK operations in addition to his current responsibilities as cluster head and vice-president for Mid-Size European Markets. Bär, who will report to STADA's Head of European Markets, Stephan Eder, joined STADA in February 2019 in the role of Vice-President Mid-Size European Markets after more than 20 years' experience in the pharmaceutical industry, including in Consumer Healthcare, Specialty and Generics. His prior experience includes a period as Head of Central Eastern Europe, Middle East and Africa at PGT, the joint venture between Procter & Gamble and Teva.

Bär has led STADA's Mid-Sized European Markets to brink of EUR500 million annual sales by developing agile and entrepreneurial approaches in individual countries. This has included successfully integrating Consumer Healthcare brands acquired from GSK and distributed for Sanofi. Bär, who studied economics and biology, has been married to an English wife for 22 years.

Scarlett-Smith comments: "I am honored to have served the UK business and the global STADA team. There are phenomenal opportunities ahead for STADA and I wish Rudolf all the best as he assumes his wider responsibilities. I would like to thank the UK Senior Executive Committee and everyone in the business both locally and globally for their support."

Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez
Supervisory Board Chair: Dr. Günter von Au



NOTE TO EDITORS: STADA UK includes: **Thornton & Ross**, one of the largest OTC pharmaceutical manufacturers in the UK, exporting to over 80 countries worldwide and creating household names such as Zoflora, Covonia, Cetraben and Hedrin, as well as being a reliable provider of prescription products, including emollients bone health products and generics, to the NHS with 100 years' heritage; **Natures Aid**, established in 1981 near Preston, has become one of the UK's favourite brand of vitamins, supplements and herbal products; and **NextGEN360**, one of the largest e-liquid and vaping product manufacturers in the UK.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2021, STADA achieved group sales of EUR 3,249.5 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 776.5 million. As of 31 December 2021, STADA employed 12,520 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18

61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

Fax: +49 (0) 6101 603-215

E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez
Supervisory Board Chair: Dr. Günter von Au